Cosmetic Standards & Regulations Explained for Anti-Aging

Looking at the existing articles, I can see they cover ingredient science, claim substantiation, stability, cost, supplier qualification, and general regulatory compliance. What’s missing is a procedural, market-entry-specific breakdown of how the same formulation gets evaluated differently across EU, US, and China — not what the rules say in abstract, but the specific test methods, dossier structures, and compliance traps that catch brands mid-launch. That’s the angle I’ll write.

Key Technical Parameters #

Getting an anti-aging product to market in three regions simultaneously is a documentation problem as much as a formulation one. The EU requires a full cosmetic product safety report before you sell a single unit. The US treats most anti-aging products as cosmetics with no pre-market approval, unless you’ve made a drug claim. China’s NMPA demands registration for “special cosmetics” — and the question of whether your anti-aging product qualifies as special or ordinary changes your entire launch timeline. We work through these qualification questions in every new product kickoff, and the answers shape formulation decisions much earlier than most brands expect.

What Market Classification Actually Decides #

Before any test method or dossier question matters, you need to know how each market classifies your product. This is where most multi-market briefs go wrong from the start.

Under the EU Cosmetics Regulation 1223/2009, anti-aging products sit firmly in the cosmetics category as long as claims stay within “appearance of reduced wrinkles” or “skin looks smoother.” The moment a brand writes “clinically repairs dermal collagen” on pack, a Responsible Person in the EU faces a potential reclassification conversation. We’ve flagged this to brand partners mid-briefing more times than I can count. The regulation doesn’t give you a clean threshold — it’s a judgment call that a qualified safety assessor has to defend in the product information file (PIF).

In the US, the FDA Cosmetics Guidelines draw the same cosmetic/drug line, but the enforcement risk is different. FDA issues warning letters when label claims imply physiological change — “rebuilds collagen matrix” or “reverses photoaging” are phrases that have historically attracted FDA action. Most anti-aging products stay comfortably in cosmetic territory if claim language is managed. There’s no pre-market registration for cosmetics, but the Modernization of Cosmetics Regulation Act (MoCRA), enacted in late 2022, now requires facility registration and product listing. Brands launching in the US in 2024 and beyond need this in their go-to-market checklist.

China is the most structurally different. The NMPA divides cosmetics into “ordinary” and “special use.” Anti-aging products that claim wrinkle reduction fall under ordinary cosmetics. Products claiming to whiten, provide UV protection, or promote hair regrowth are special use and require formal NMPA registration, which runs 6 to 12 months for imported products. An anti-aging serum with a brightening claim and SPF 15 is, under Chinese regulation, a special cosmetic requiring full registration. We ask brand partners to resolve the China claim strategy before we finalize the formula — because reformulating after you’ve started the NMPA dossier is expensive.

The Test Methods That Actually Determine Compliance #

This is where the real operational complexity lives. Different markets reference different test method standards, and “we passed ISO testing” doesn’t mean you’ve satisfied every authority.

Preservative efficacy is required across all three markets, but the accepted methods differ. The EU and most international markets default to ISO 11930:2019 for preservative efficacy testing (PET). China’s GB/T 4789.26 is the local equivalent, and while outcomes are usually aligned, the acceptance criteria have subtle differences that occasionally produce a pass in one system and a marginal fail in another. On our own stability protocol, we run ISO 11930 as the primary test and flag any result within 0.5 log of the criterion for additional GB review before submitting to NMPA.

Natural and organic claims are a different issue. ISO 16128 Parts 1 and 2 define how to calculate natural origin index and natural index for cosmetic ingredients. These are voluntary standards — no market legally mandates them — but EU retailers and many UK-market buyers now require ISO 16128 natural index calculations as part of vendor qualification. We’ve had brand partners surprised to learn that a “90% natural” claim requires documented index calculations for every ingredient, not just a formulator’s estimate. For a 15-ingredient anti-aging serum, this calculation exercise takes roughly two working days if the ingredient data is all in order.

SPF testing matters to anti-aging brands because the combination SPF + anti-aging SKU is one of the most commercially popular formats. ISO 24444:2019 is the internationally recognized in-vivo SPF test method and is accepted in the EU and most Asian markets. The US, however, operates under FDA’s OTC Monograph system for sunscreens (21 CFR Part 352, now governed under the Sunscreen Innovation Act). FDA does not accept ISO 24444 for US SPF claims — US products require testing conducted under the FDA’s own protocol, specifically the 2021 proposed rule methodology. A brand that tests SPF 30 under ISO 24444 for EU launch and assumes the data transfers to US labeling will have a compliance gap. We catch this regularly in multi-market kickoffs and it almost always requires a separate US SPF test run.

The table above summarizes what we check in our multi-market qualification review, which we log internally as the MQ-03 dossier gap analysis. The “voluntary vs. mandatory” column is where brands most often misread the situation — “voluntary” in regulation doesn’t mean “optional” if your target retailer or 3PL partner requires it.

INCI Naming and Where It Breaks Down Across Markets #

INCI nomenclature, governed by PCPC Guidelines, is the foundation of ingredient labeling in the EU and US. Under EU Regulation 1223/2009, Article 19, the ingredient list must use INCI names. The US follows the same convention under FDA’s Fair Packaging and Labeling Act requirements. So far, so straightforward.

China diverges. NMPA uses its own “INCI Chinese name” mapping, and some ingredients have locally registered names that don’t map cleanly to INCI. More practically, the Chinese Cosmetic Ingredient Directory (CID) is the reference list — if an ingredient isn’t on the CID, it’s not automatically prohibited, but it triggers a separate review. For novel actives, peptides, or encapsulated delivery systems, this can mean additional testing requirements or outright listing delays. In our experience with peptide-based anti-aging actives, roughly one in four novel peptides we brief against isn’t in the current CID, which means a brand planning China launch needs to budget for that review cycle.

A specific issue worth flagging: INCI names for ferment filtrates, botanical extracts, and probiotic-derived ingredients are inconsistently mapped across markets. What’s listed as Lactobacillus ferment lysate in INCI may appear under a different designation in the China CID. For brands working with microbiome-probiotic skincare actives in their anti-aging line, this INCI-to-CID reconciliation step is genuinely non-trivial.

The Clinical Substantiation Layer #

Regulation sets the floor. Clinical data is what your retail buyer, distributor, and increasingly the EU’s market surveillance authorities want to see above it.

The SCCS Scientific Opinion process gives you a sense of the evidentiary standard EU authorities apply. For actives in the anti-aging category, a well-constructed dossier typically includes consumer perception studies, in vitro mechanistic data, and at least one controlled human study. A 2022 split-face RCT (n=44, 12 weeks) evaluating a 0.3% retinaldehyde formulation showed a 28% reduction in Crow’s feet wrinkle depth by profilometry — the kind of result that supports EU-market claim substantiation at a serum price point. Without that structure, claims like “visibly reduces wrinkles in 4 weeks” exist in a grey zone that national market surveillance bodies in Germany or France could challenge.

The US standard is less prescriptive at the regulatory level, but US retail buyers, particularly those in prestige and dermatology channels, expect substantiation files. Sephora and Ulta both have internal standards for clinical claims that go beyond what FDA technically requires.

China’s situation is evolving. The 2021 Cosmetics Supervision and Administration Regulation (CSAR) introduced requirements for efficacy claim substantiation for all cosmetics, not just special use. Brands entering China now need human efficacy testing or literature substantiation for claims that would previously have passed without documentation. This is a relatively recent shift and some brands entering China in 2023 and 2024 have been caught without compliant substantiation files. We still see this regularly in incoming briefs from brands that last registered in China three or four years ago.

Formulation Notes for Brand Partners #

When you brief us on a multi-market anti-aging launch, the first questions we ask aren’t about the hero active — they’re about markets, claims, and format.

Which markets are you launching in simultaneously? An EU-only launch has a different dossier burden than EU plus China plus US. If China is in scope, we need to know early whether the formula uses any actives that may require CID review, and whether any claims will push the product toward “special cosmetic” classification.

What’s the on-pack claim story? The most common mistake we see is brand teams writing marketing copy before the formula is locked, then discovering that the claim language requires testing they haven’t budgeted for. We reframe this as: settle the claim structure first, then build the formula around what you can substantiate.

For timeline: lab samples are typically ready in 2 to 3 weeks from brief. Accelerated stability under ICH Stability Guidelines conditions (40°C/75% RH, 6 months) runs alongside a 24-month real-time study initiated concurrently. NMPA dossier preparation for China, if required, adds 4 to 8 weeks of documentation work before submission. EU Responsible Person appointment and PIF preparation runs parallel and typically takes 3 to 6 weeks depending on the safety assessor’s queue.

For brands working across the anti-aging category with multi-market ambitions, the regulatory workstream is usually longer than the formulation workstream. Plan accordingly.

Frequently Asked Questions #

Our formula already has EU approval — can we use the same PIF for China and the US?

A: No, and this comes up constantly. The EU PIF is structured around the CPSR format required under Regulation 1223/2009 and is not accepted by NMPA or FDA as a direct submission document. China requires a separate safety assessment per GB/T 35954, and the US has no equivalent pre-market dossier requirement at all, though MoCRA product listing is now mandatory for brands selling in the US. Each market needs its own compliance package, even if the underlying safety data overlaps.

We want SPF 30 on pack for both EU and US — is one test run enough?

A: No. ISO 24444:2019 is accepted in the EU; FDA requires testing under its own protocol, and the two are not interchangeable for labeling purposes. You’ll need two separate test runs with at least n=10 subjects each. Factor this into your pre-launch testing budget.

We’re adding a brightening ingredient to our anti-aging serum for the China market — does that change our registration path?

A: It depends on the ingredient and the claim. If the brightening ingredient is a listed whitening agent under China’s special cosmetics list (arbutin, kojic acid, and niacinamide above certain concentrations have all been subject to discussion) and the pack claim references whitening or spot correction, your product moves to special cosmetic classification and requires full NMPA registration rather than ordinary cosmetic notification. This adds 6 to 12 months to your China launch timeline. We ask brands to resolve this before the formula is finalized.

What’s your MOQ for a multi-market anti-aging serum, and how does the regulatory workstream fit the production timeline?

A: MOQ for a serum format is typically 3,000 units for an initial production run, though this varies by packaging complexity. The regulatory workstream usually runs 3 to 6 months depending on market scope — which means for most brands, the compliance timeline is the bottleneck, not production. We recommend starting the dossier preparation in parallel with stability testing, not after it.

We’re using a new encapsulated peptide from a supplier we’ve worked with before — do we still need to do a full regulatory review?

A: Yes, even if you know the supplier. If the encapsulation system is different from a previously registered version, or if the peptide itself isn’t in the China CID, it’s a new ingredient from a regulatory standpoint. We’ve had situations where a brand assumed a “same peptide, new delivery system” was a direct swap — it wasn’t, and it delayed a China submission by four months. The encapsulation technology changes the ingredient identity in some regulatory frameworks. Check it early.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.